University of North Carolina Global HIV Prevention and Treatment Clinical Trials

描述(由申请者提供)：北卡罗来纳大学(UNC)全球艾滋病毒临床试验单位(CTU)在高质量、创新的临床试验方面有着良好的记录 研究，强大的科学领导(NIH艾滋病毒/艾滋病网络内外)，以及接触到美国东南部和南部非洲的关键重要感染者和高危人群。我们的CTU来自两大洲的不同临床研究人员团队，将由三名经验丰富的首席研究人员(Joseph Eron MD、Jeffrey Stringer MD和Mina Hosseiniour MD)领导，并将支持NIH艾滋病毒临床试验网络的所有5个网络：成人治疗战略、应对儿童和母亲人口中艾滋病毒和艾滋病毒相关感染的战略、艾滋病毒综合预防战略、杀微生物剂战略和预防艾滋病毒感染的疫苗战略。这5个临床研究网站(CRS)将包括由David Wohl MD(成人治疗战略、综合预防、杀微生物剂和疫苗)领导的Chapel Hill CRS、由Kristine Patterson MD(成人治疗战略、综合预防、疫苗)领导的Raleigh CRS、由Cornelius Van Dam MD博士领导的Greensboro CRS(成人治疗战略和综合预防)、由Francis Martinson MD博士领导的马拉维CRS(全部5个网络)和由Benjamin chi MD领导的赞比亚CRS(全部5个网络)。支持这一领导的将是网络科学团队，这些团队由全球专家和现场合作者组成，他们将致力于执行网络科学议程。CTU还召集了一批不同的高级科学家和公共卫生官员，为我们的科学和战略咨询小组服务。反恐联盟行政部门采用了一个高度有组织的结构，该结构将对我们在5个地点的经验丰富的研究团队做出反应，并将提供持续的评估，以确保最佳的业绩和效率。CTU将得到最先进的通信技术的支持，并已汇集了优秀的实验室、药房、质量保证、数据管理和监管支持。凭借其强大的管理框架，北卡罗来纳大学全球艾滋病毒CTU将处于独特的地位，可以提供科学领导和临床试验基础设施，以推动非艾滋病网络议程领域的发展。

DESCRIPTION (provided by applicant): The University of North Carolina (UNC) Global HIV Clinical Trials Unit (CTU) has a well established track record of high-quality, innovative clinical research, strong scientific leadership (both in and outside the NIH HIV/AIDS Networks), and access to critically important infected and at-risk populations in the Southeastern US and in Southern Africa. Drawn from a diverse team of clinical innvestigators spanning two continents, our CTU will be led by three experienced principal investigators (Joseph Eron MD, Jeffrey Stringer MD and Mina Hosseinipour MD) and will support all 5 NIH HIV Clinical Trials Networks: Adult Therapeutic Strategies, Strategies to Address HIV and HIV-associated Infections in Pediatric and Maternal Populations, Integrated HIV Prevention Strategies, Microbicide Strategies, and Vaccine Strategies to Prevent HIV Infection. The 5 Clinical Research Sites (CRS) will include Chapel Hill CRS led by David Wohl MD (Adult Therapeutic Strategies, Integrated Prevention, Microbicide and Vaccine), Raleigh CRS led by Kristine Patterson MD (Adult Therapeutic Strategies, Integrated Prevention, Vaccine), Greensboro CRS led by Cornelius Van Dam MD PhD (Adult Therapeutic Strategy and Integrated Prevention), Malawi CRS led by Francis Martinson MD PhD (all 5 Networks) and Zambia CRS led by Benjamin Chi MD (all 5 Networks). Supporting this leadership will be Network Science Teams, comprising global experts and site collaborators who will work to execute the network scientific agendas. The CTU has also assembled a diverse group of senior scientists and public health officials to serve on our Scientific and Strategic Advisory Group. The CTU administration incorporates a highly organized structure that will be responsive to our experienced research teams across the 5 sites and will provide ongoing evaluation to ensure optimal performance and efficiency. The CTU will be supported by state-of-the-art communications and has assembled outstanding laboratory, pharmacy, quality assurance, data management and regulatory support. With its robust administrative framework, the UNC Global HIV CTU will be uniquely positioned to provide scientific leadership and clinical trials infrastructure to advance the field of agenda of he NlAID networks.